Merck launches HME excipient with high API loading capacity

By Gareth Macdonald

- Last updated on GMT

iStock/Antoine2K
iStock/Antoine2K

Related tags Pharmacology

Merck has launched a polyvinyl alcohol-based excipient developed for use in drugs produced via hot melt extrusion (HME).

The excipient – Parteck MXP – is stable at temperatures of up to 200 degrees Celsius and can achieve active pharmaceutical ingredient (API) loads of more than 30% by weight. Most commercially available HME excipients have load capacities in the 10 – 15% range.

Germany-based Merck has used the excipient to develop formulations of a range of APIs, including ibuprofen, indomethacin and itraconazole.

Rachel Bloom-Baglin, Head of External & Executive Communications at the life science business of Merck, told us the high loading capacity has potnetial benefits for patients and manufacturers.

Most of the products on the market have some limitation in the amount of API which can be loaded.​"

Having a high drug load leads to fewer limitations on the dose strength that can be made into a single tablet​,” she said, adding “It also leads to smaller pill size, fewer number of pills which need to be taken in a dose and cost efficiencies in manufacturing because more tablets and capsules can be made from each batch​.” 

Partech MXP will be manufactured at Merck's site in Darmstadt, Germany according to Bloom-Baglin, who told us "The cost of the product is comparable to other polymers used in HME processes.​"

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...